ZACCARDELLI DAVID

VRNA CEO David Zaccardelli sold 208,912 shares at $13.14 on 2025-08-01; stock rose +52.4% in 90 days post-transaction.

David Zaccardelli, President and CEO, sold 208,912 shares (208.9K shares) of Verona Pharma at $13.14, representing a 1.5% reduction in his 13.38M-share post-transaction holdings. The transaction occurred when the stock subsequently posted a 90-day return of +52.4%, indicating the sale was poorly timed relative to near-term price appreciation. Across his prior trades at VRNA (5 distinct transactions), his same-ticker timing shows 0 of 1 measurable 90-day outcomes were well-timed, and his cross-ticker track record reflects a 0.00% well-timed rate across 20 prior sells, suggesting a consistent pattern of selling before rallies rather than before declines. The company remains unprofitable (net income of $-16.3M on $76.3M revenue in the latest quarter), but the CEO's small relative share reduction and the stock's strong momentum post-transaction do not present material governance or transparency concerns at this time.

CEO David Zaccardelli sold 400,000 shares of VRNA at $11.40 on 2025-06-11, retaining 13.19M shares post-sale in unprofitable company.

David Zaccardelli, President and CEO, sold 400,000 shares at $11.40, reducing his holdings to 13,190,168 shares while retaining substantial ownership. The company reported revenue of $76,256,000.00 in its latest quarter but posted a net loss of $-16,319,000.00 and was unprofitable over its most recent full fiscal year. Stock price has risen 37.1% in the past 30 days and 50.2% in the past 90 days, currently trading at $92.20—near its 52-week high of $92.50. Across his cross-ticker track record, Zaccardelli's sells have exhibited a 0.00% well-timed rate at the 90-day mark, indicating his prior sales have been poorly-timed (stock subsequently rose). At the same ticker, his three most recent sales on 2025-05-29, 2025-05-28, and 2025-05-27 lack measurable outcomes. The sale occurred during a period of significant stock appreciation in an unprofitable company, which may merit observation given the fundamental backdrop.

Verona Pharma CEO sells 400,000 shares ($3.7M) across 3 days at avg $9.34; stock now at $77.49

David Zaccardelli, President and CEO, executed 3 separate sales totaling 400,000 shares for $3,734,578.83 on 2025-05-27 through 2025-05-29 at prices ranging from $9.30 to $9.53. The transaction occurred at a blended average price of $9.34, while the current stock price stands at $77.49—representing a stark 730% spread between the transaction prices and today's market. Zaccardelli retained 13,590,168 shares post-transaction, reducing his holdings by 2.9%. The company is unprofitable with a net income of $-16,319,000.00 in the latest quarter, yet carries a market capitalization of $52,775,031,144.78. His prior 5 trades at Verona show mixed timing outcomes: one 2024 sale generated substantial 30-day and 90-day returns (+830.2% and +1211.1%), while more recent sales from April and May show only partial outcome visibility, with only 0 of 1 measurable prior sales well-timed at the 90-day mark.

VRNA CEO David Zaccardelli sells 587,008 shares across 3 transactions for $5,311,279.00; remains 13.99M shareholder

David Zaccardelli, President and CEO of Verona Pharma, executed 3 separate open-market sales totaling 587,008 shares for $5,311,279.00 at a blended average price of $9.05 per share on 2025-05-01 and 2025-05-02, reducing his holdings by 4.0% to 13.99M shares. The transaction occurred when the current stock price stands at $72.25—substantially above the transaction prices—suggesting the sales were executed well below recent market valuations. His prior sales at VRNA show a consistent pattern of poor timing on a 90-day basis: 4 measurable prior trades at this ticker show 0 of 4 were well-timed at the 90-day mark, with average 90-day returns ranging from +828.8% to +1292.6%, indicating the stock has risen significantly after his prior exits. The company remains unprofitable (net income $-16.3M in the latest quarter) despite $76.3M in quarterly revenue, creating a backdrop of operational challenges alongside elevated valuation at the current price level.

CEO Zaccardelli sold 90,360 shares of VRNA at $8.98 on 2025-04-29 for $811,432.80; stock now $72.26.

David Zaccardelli, President and CEO, sold 90,360 shares (-0.6% of pre-transaction holdings) at $8.98, retaining 14.38M shares. The stock has since moved significantly upward: it is currently at $72.26, compared to the $8.98 transaction price, and has advanced +23.4% over 30 days and +26.1% over 90 days. At VRNA specifically, Zaccardelli's prior three measurable sales (December 2024) were followed by average 90-day returns of +1,211.1%, +1,247.3%, and +1,249.5%; none of those prior sells proved well-timed (the stock rose substantially afterward). The company is unprofitable, reporting $-16.3M net income against $76.3M quarterly revenue, which contextualizes the volatility in the stock price. This sale occurred at a dramatically lower price relative to current levels, but fits a pattern where the insider's prior VRNA sales have consistently been followed by upward moves rather than declines.

CEO David Zaccardelli sold 870.7K shares (5.8% of holdings) at $5.01 avg across three days (Dec 4–6), netting $4.4M, while stock currently trades at $40.50.

David Zaccardelli, President and CEO of Verona Pharma, executed 3 separate sales totaling 870,672 shares for $4,358,787.38 on December 4–6, 2024, at a blended average price of $5.01. The stock now trades at $40.50, representing an 708% appreciation since his sales. His prior trades at VRNA show an identical pattern: two sales on November 1 and November 4 delivered 30-day returns of +805.6% and +807.4% respectively, yet the stock continued climbing, indicating poorly timed exits. The company's fundamentals reveal a stark deterioration with Annual revenue growth of -100.0%, net losses of $-42,962,000.00, and minimal quarterly revenue of $5,624,000.00. The timing of these sales—executed at significant discounts to current trading levels despite the company's unprofitable status—warrants investor attention given the CEO's consistent pattern of selling ahead of substantial rallies at this ticker.

CEO Zaccardelli sells 125,328 shares ($627.2K) across 3 trades; 90-day timing rate 0% on same-ticker prior sales

David Zaccardelli, President and CEO of Verona Pharma, executed 3 separate open-market sales totaling 125,328 shares (125.3K shares) for $627,233.33 ($627.2K) between November 27 and December 2, 2024, at a blended average price of $5.00. The sales represent a -0.8% reduction against his pre-transaction holdings of 15,200,752 shares (15.20M shares). His prior 5 trades at VRNA have all been sells, and none showed positive outcomes at the 90-day mark where measurable (all five prior trades at this ticker posted 30-day gains, but timing pattern on VRNA is 0 of 0 well-timed at 90 days). While the company's fundamentals show material challenges—annual revenue growth of -100.0% and a net loss of $-42,962,000.00 ($-43.0M) for the most recent full year—the sales occurred near the stock's 52-week high ($39.11 current price is -2.0% from the $39.90 peak), and the stock has posted strong recent momentum (+11.8% over 30 days, +43.7% over 90 days prior to these trades). The concentrated selling activity by the CEO warrants investor attention given the divergence between recent positive price momentum and the company's underlying unprofitable operational performance.

Verona Pharma CEO Zaccardelli sells 141,032 shares ($618.7K) in two tranches at $4.38–$4.39; stock now trades at $38.39 (+19.9% in 30 days)

David Zaccardelli, President and CEO of Verona Pharma, executed 2 separate sales totaling 141,032 shares for $618,657.57, with transactions priced at $4.38 on 2024-11-01 and $4.39 on 2024-11-04. The stock has since surged to $38.39, representing a 777% move above the transaction prices and a +19.9% gain over the past 30 days. His cross-ticker track record shows sells with an average 90-day return of +494.3% and a 0.00% well-timed rate, indicating his prior open-market sales elsewhere have systematically preceded upward moves. At VRNA specifically, he executed 5 prior sales over consecutive days (2024-10-21 through 2024-10-25) with outcomes not yet measurable. These rapid back-to-back sales, paired with the stock's dramatic appreciation post-transaction and the company's challenging fundamentals (annual revenue growth of -100.0%, net income of -$42,962,000), suggest the market has significantly repriced the asset since the insider's near-identical-priced disposals. The magnitude of the mismatch between sale prices (~$4.39) and current market price ($38.39) warrants investigation into whether intervening developments—clinical data, partnership news, or other catalysts—have driven the revaluation, or whether the initial sales represented a disconnect between insider activity and subsequent market sentiment.

CEO David Zaccardelli sold 144,816 shares at $4.38 across 3 days (Oct 23–25); stock now at $33.86, up 49.0% in 90 days.

David Zaccardelli, President and CEO of Verona Pharma, executed 3 separate sales totaling 144,816 shares for $633,895.84 at an average price of $4.38 per share on October 23–25, 2024. The current price of $33.86 stands 671% above the transaction price, and the stock has posted a 90-day return of +49.0% and 30-day return of +19.8%, indicating a sharp and sustained ascent after the insider's sales. His post-transaction holdings of 14,591,736 shares represent a -1.0% reduction in stake. While his cross-ticker track record shows a 90-day well-timed sell rate of 0.00% (no measurable gains avoided), this particular sale preceded substantial stock appreciation, making the timing signal notably unfavorable relative to subsequent price discovery. The company remains unprofitable (net income of -$70,835,000.00), yet the market valuation has swelled to $22.0B, warranting scrutiny into whether the sale reflected a deliberate reduction in a momentum-driven position or a discretionary transaction divorced from fundamental risk.

VRNA CEO Zaccardelli sold 514,152 shares (514.2K) for $2.3M at $4.38 avg; stock now $34.87, up 16.3% in 30d

David Zaccardelli, President and CEO of Verona Pharma, executed 3 separate sales totaling 514,152 shares for $2,253,236.59 between October 18–22, 2024, at a blended average price of $4.38. The current price is $34.87—substantially higher than the transaction prices—representing a 30-day gain of 16.3% and a 90-day gain of 65.5% from the filing date. The insider retains 14.74M shares post-transaction (a 3.4% reduction in holdings), indicating this does not represent a material exit. Critically, at VRNA specifically, Zaccardelli's 5 prior sales show dramatic post-sale appreciation: 30-day returns of +680.8% to +863.3%, yet the one measurable 90-day outcome (2023-08-07 sale) yielded +522.8%—positive, meaning the stock rose after he sold, making that sale poorly timed. The current spike may reflect a significant clinical or commercial development; investors should assess whether the stock's sharp appreciation since the sale reflects new material information or market momentum.